Skip to main content
. 2024 Dec 23;17:17562848241307596. doi: 10.1177/17562848241307596

Table 6.

New-onset clinical outcomes following UST treatment during the follow-up period.

Clinical outcomes Early UST use (n = 105) Late UST use (n = 132) p Value
Composite outcome, n (%) 16 (15.2) 51 (38.6) <0.001
Hospitalization, n (%) 13 (12.4) 39 (29.5) 0.002
Treatment escalation, n (%) 7 (6.7) 30 (22.7) <0.001
Behavior progression, n (%) 10 (9.5) 19 (14.4) 0.256
CD-related surgeries, n (%) 7 (6.7) 11 (8.3) 0.630

CD, Crohn’s disease; UST, Ustekinumab.